



**Arizona Cancer Registry**

**Index Guide** for the:

Commission on Cancer Facility Oncology Registry Data Standards, Revised for 2009 and the Arizona Cancer Registry Supplement Effective for Cases Diagnosed January 1, 2009

NAACCR Item Name	NAACCR Item #	Required	FORDS & ACR Supplement Page #	PDF Page #
<b>Patient Identification</b>				
Type of Reporting Source	500	Y	32A	68
Casefinding Source	501	Y	32B	69
Accession Number	550	Y	33	71
Sequence Number	560	Y	34	72
Medical Record Number	2300	Y	36	74
Social Security Number	2320	Y	37	75
Military Medical Record Number Suffix	2310	N	38	76
Last Name	2230	Y	39	77
First Name	2240	Y	40	78
Name-Maiden	2390	Y	40A	79
Name-Alias	2280	Y	40B	80
Name-Suffix	2270	N	40C	81
Middle Name (Middle Initial)	2250	Y	41	83
Patient Address (Number and Street) at Diagnosis	2330	Y	42	84
Patient Address at Diagnosis-Supplemental	2335	Y	43	89
City/Town at Diagnosis (City or Town)	70	Y	44	90
State at Diagnosis (State)	80	Y	45	91
Postal Code at Diagnosis (Zip Code)	100	Y	47	93
County at Diagnosis	90	Y	48	94
Patient Address (Number and Street)-Current	2350	Y	49	95
Patient Address-Current-Supplemental	2355	N	50	96
City/Town-Current	1810	Y	51	97
State-Current	1820	Y	52	98
Postal Code-Current (Zip Code)	1830	Y	54	100
Telephone	2360	N	55	101
Place of Birth	250	Y	56	102
Date of Birth	240	Y	57	105
Age at Diagnosis	230	Y	58	106
Race 1	160	Y	59	111
Race 2	161	Y	61	113
Race 3	162	Y	62	114
Race 4	163	Y	63	115
Race 5	164	Y	64	116
Spanish Origin-All Sources (Spanish/Hispanic Origin)	190	Y	65	117
Sex	220	Y	66	118
Marital Status at Dx	150	Y	66A	119
Text-Usual Occupation	310	Y	66B	120
Occupation Code-Census	270	ACR Use Only	66C	121
Text-Usual Industry	320	Y	66D	122
Industry Code-Census	280	ACR Use Only	66E	123
Name-Spouse/Parent	2290	Y	66F	124
Follow-up Contact-Name	2394	Supplemental	66G	125
Follow-up Contact-Phone Num	N/A	Supplemental	66G	125

NAACCR Item Name	NAACCR Item #	Required	FORDS & ACR Supplement Page #	PDF Page #
Follow-up Contact-Phone Type	N/A	Supplemental	66G	125
Follow-up Contact-Relation	N/A	Supplemental	66G	125
Follow-up Contact-No&St	2392	Supplemental	66G	125
Follow-up Contact-Suppl	2393	Supplemental	66G	125
Follow-up Contact-City	1842	Supplemental	66G	125
Follow-up Contact-State	1844	Supplemental	66G	125
Follow-up Contact-Postal	1846	Supplemental	66G	125
Primary Payer at Diagnosis	630	Y	67	127
Comorbidities and Complications #1	3110	N	69	129
Comorbidities and Complications #2	3120	N	71	131
Comorbidities and Complications #3	3130	N	72	132
Comorbidities and Complications #4	3140	N	73	133
Comorbidities and Complications #5	3150	N	74	134
Comorbidities and Complications #6	3160	N	75	135
Comorbidities and Complications #7	3161	N	75A	136
Comorbidities and Complications #8	3162	N	75B	137
Comorbidities and Complications #9	3163	N	75C	138
Comorbidities and Complications #10	3164	N	75D	139
NPI-Managing Physician	2465	N	75E	140
Following Physician (Follow-Up Physician)	2470	Y	76	141
NPI-Following Physician	2475	Y	76A	142
Primary Surgeon	2480	N	77	143
NPI-Primary Surgeon	2485	N	77A	144
Physician #3 (Other Physician)	2490	N	78	145
NPI-Physician #3 (Radiation Oncologist-CoC Preferred)	2495	N	78A	146
Physician #4 (Other Physician)	2500	N	79	147
NPI-Physician #4 (Medical Oncologist-CoC Preferred)	2505	N	79A	148
<b>Cancer Identification</b>				
Class of Case	610	Y	83	151
Date of Inpatient Adm	590	Y	84A	153
Date of Inpatient Disch	600	Y	84B	154
Facility Referred From	2410	N	85	155
NPI-Institution Referred From	2415	N	85A	156
Facility Referred To	2420	N	86	157
NPI-Institution Referred To	2425	N	86A	158
Date of First Contact	580	Y	87	159
Date of Initial Diagnosis	390	Y	89	163
Text-Primary Site Title	2580	Y	90A	165
Primary Site	400	Y	91	169
Laterality	410	Y	92	170
Text-Histology Title	2590	Y	92A	171
Histology	522	Y	93	173
Behavior Code	523	Y	94	174
Grade/Differentiation	440	Y	96	176
Other Primary Tumors	N/A	Y	98D	183
Text-Dx Proc-Path	2570	Y	98E	184
Diagnostic Confirmation	490	Y	99	185
Ambiguous Terminology Diagnosis	442	Y	99A	186
Date of Conclusive Diagnosis	443	Y	99C	188
Date of Multiple Tumors	445	Y	99E	190
Multiple Tumors Reported as One Primary	444	Y	99G	192
Multiplicity Counter	446	Y	99H	193

NAACCR Item Name	NAACCR Item #	Required	FORDS & ACR Supplement Page #	PDF Page #
Tumor Size	780	Y	100	195
Description of Size	N/A	Y	101A	197
Regional Lymph Nodes Examined	830	Y	102	199
Regional Lymph Nodes Positive	820	Y	103	201
<b>Stage of Disease at Diagnosis</b>				
Date of Surgical Diagnostic & Staging Procedure	1280	Y	107	205
Surgical Diagnostic & Staging Procedure	1350	Y	109	207
Surgical Diagnostic & Staging Procedure at this Facility	740	Y	111	209
Clinical T	940	Y*	112	210
Clinical N	950	Y*	113	211
Clinical M	960	Y*	114	212
Clinical Stage Group	970	Y*	115	213
Clinical Stage (Prefix/Suffix) Descriptor	980	N	116	214
Staged By (Clinical Stage)	990	Y*	117	215
Pathologic T	880	Y*	118	216
Pathologic N	890	Y*	119	217
Pathologic M	900	Y*	120	218
Pathologic Stage Group	910	Y*	121	219
Pathologic Stage (Prefix/Suffix) Descriptor	920	N	122	220
Staged By (Pathologic Stage)	930	Y*	123	221
SEER Summary Stage 2000	759	Y*	124	222
Text-Staging	2600	Y	124A	223
Text-DX Proc-Xray/Scan	2530	Y	124B	224
Text-DX Proc-Lab Tests	2550	Y	124C	225
Text-DX Proc-PE	2520	Y	124D	226
Text-DX Proc-OP	2560	Y	124E	227
Text-DX Proc-Scopes	2540	Y	124F	228
CS Tumor Size	2800	Y	125	229
CS Extension	2810	Y	125C	230
CS Tumor Size/Ext Eval	2820	Y	125E	231
CS Lymph Nodes	2830	Y	125H	232
CS Reg Nodes Eval	2840	Y	125J	233
CS Mets at Dx	2850	Y	125L	234
CS Mets Eval	2860	Y	125M	235
CS Site-Specific Factor 1	2880	Y	125O	236
CS Site-Specific Factor 2	2890	Y	125Q	237
CS Site-Specific Factor 3	2900	Y	125R	238
CS Site-Specific Factor 4	2910	Y	125S	239
CS Site-Specific Factor 5	2920	Y	125T	240
CS Site-Specific Factor 6	2930	Y	125U	241
Derived AJCC T	2940	Y	125V	242
Derived AJCC T Descriptor	2950	Y	125W	243
Derived AJCC N	2960	Y	125X	244
Derived AJCC N Descriptor	2970	Y	125Y	245
Derived AJCC M	2980	Y	125Z	246
Derived AJCC M Descriptor	2990	Y	125AA	247
Derived AJCC Stage Group	3000	Y	125BB	248
Derived SS1977	3010	Y	125DD	250
Derived SS2000	3020	Y	125EE	251
<b>First Course of Treatment</b>				
Hospital	N/A	Y	128A	255

\*See FORDS manual for complete requirements

<b>NAACCR Item Name</b>	<b>NAACCR Item #</b>	<b>Required</b>	<b>FORDS &amp; ACR Supplement Page #</b>	<b>PDF Page #</b>
Date of First Course of Treatment	1270	Y	129	257
Date of First Surgical Procedure	1200	Y	131	259
Date of Most Definitive Surgical Resection of the Primary Site	3170	Y	133	261
Rx Text-Surgery	2610	Y	134A	263
Surgical Procedure of Primary Site	1290	Y	135	265
Surgical Procedure of Primary Site at This Facility	670	Y	136	266
Surgical Margins of the Primary Site	1320	Y	137	267
Scope of Regional Lymph Node Surgery	1292	Y	138	268
Scope of Regional Lymph Node Surgery at this Facility	672	Y	140	270
Surgical Procedure/Other Site	1294	Y	142	272
Surgical Procedure/Other Site at This Facility	674	Y	143	273
Date of Surgical Discharge	3180	N	144	274
Readm. to the Same Hospital within 30 days of Surg. Disch.	3190	N	146	276
Reason for No Surgery of Primary Site	1340	Y	147	277
Date Radiation Started	1210	Y	148	278
Location of Radiation Treatment	1550	N	150	280
Rx Hosp-Radiation	690	Y	150A	281
Rx Summ-Radiation	1360	Y	150B	282
Rx Text-Radiation (Beam)	2620	Y	150C	283
Rx Text-Radiation (Other)	2630	Y	150D	284
Radiation Treatment Volume	1540	N	151	285
Regional Treatment Modality	1570	Y	155	291
Regional Dose: cGy	1510	N	158	294
Boost Treatment Modality	3200	N	159	295
Boost Dose: cGy	3210	N	162	298
Number of Treatments to This Volume	1520	N	163	299
Radiation/Surgery Sequence	1380	Y	164	300
Data Radiation Ended	3229	N	166	302
Reason for No Radiation	1430	N	168	304
Date Systemic Therapy Started	3230	Y	169	305
Rx Text-Chemo	2640	Y	170A	307
Rx Date-Chemo	1220	Y	170B	308
Chemotherapy	1390	Y	171	311
Chemotherapy at This Facility	700	Y	173	313
Rx Text-Hormone	2650	Y	174A	315
Rx Date-Hormone	1230	Y	174B	316
Hormone Therapy	1400	Y	175	319
Hormone Therapy at This Facility	710	Y	177	321
Rx Text-BRM	2660	Y	178A	323
Rx Date-BRM	1240	Y	178B	324
Immunotherapy	1410	Y	179	327
Immunotherapy at This Facility	720	Y	181	329
Hematologic Transplant & Endocrine Procedures	3250	Y	182	330
Systemic/Surgery Sequence	1639	Y	183A	332
Date Other Treatment Started	1250	Y	184	334
Other Treatment	1420	Y	186	336
Rx Text-Other	2670	Y	186A	337
Other Treatment at This Facility	730	Y	187	341
Pain Assessment	3260	N	188	342
Palliative Care	3270	Y	189	345
Palliative Care at This Facility	3280	Y	191	347
<b>Outcomes</b>				

NAACCR Item Name	NAACCR Item #	Required	FORDS & ACR Supplement Page #	PDF Page #
Date of First Recurrence	1860	Y	195	351
Type of First Recurrence	1880	Y	197	353
Date of Last Contact or Death	1750	Y	199	355
Vital Status	1760	Y	200	356
Cancer Status	1770	Y	201	357
Following Registry	2440	N	202	358
NPI-Following Registry	2445	N	202A	359
Follow-up Source	1790	N	203	360
Follow-up Source Central	1791	ACR Use Only	203A	361
Next Follow-up Source	1800	N	204	363
Describe Place of Death	N/A	Supplemental	204A	365
Place of Death	1940	Y	204B	366
Cause of Death	1910	Y	204C	367
Autopsy	1930	Y	204D	368
Letter Frequency	N/A	Y	204E	369
Text-Remarks	2680	*N	204F	370
Suspense Case	N/A	Y	204G	371
<b>Case Administration</b>				
Abstracted By	570	Y	207	375
Facility Identification Number	540	Y	208	376
NPI-Reporting Facility	545	Y	208A	377
Archive FIN	3100	Y	209	378
NPI-Archive FIN	3105	Y	209A	379
Override ACSN/CLASS/SEQ	1985	Y	210	380
Override HOSPSEQ/DXCONF	1986	Y	211	381
Override CoC-SITE/TYPE	1987	Y	212	382
Override HOSPSEQ/SITE	1988	Y	213	383
Override SITE/TNM-STAGE GROUP	1989	Y	214	384
Override AGE/SITE/MORPH	1990	Y	215	385
Override SURG/DXCONF	2020	Y	216	386
Override SITE/TYPE	2030	Y	217	387
Override Histology	2040	Y	218	388
Override Leuk, Lymphoma	2070	Y	219	389
Override SITE/BEHAVIOR	2071	Y	220	390
Override SITE/LAT/MORPH	2074	Y	221	391
CoC Coding System-Current	2140	Y	222	392
CoC Coding System-Original	2150	Y	224	394
Race Coding System-Current	170	Y	226	396
Race Coding System-Original	180	Y	227	397
Site Coding System-Current	450	Y	228	398
Site coding System-Original	460	Y	229	399
Morphology Coding System-Current	470	Y	230	400
Morphology Coding System-Original	480	Y	231	401
ICD-O-2 Conversion Flag	1980	Y	232	402
ICD-O-3 Conversion Flag	2116	Y	233	403
TNM Edition Number	1060	Y	234	404
ICD Revision Comorbidities and Complications	3165	N	234A	405
RX Coding System-Current	1460	Y	235	406
Derived AJCC-Flag	3030	Y	235A	407
Derived SS1977-Flag	3040	Y	235B	408
Derived SS2000-Flag	3050	Y	235C	409
CS Version First	2935	Y	235D	410

\*See FORDS manual for complete requirements

<b>NAACCR Item Name</b>	<b>NAACCR Item #</b>	<b>Required</b>	<b>FORDS &amp; ACR Supplement Page #</b>	<b>PDF Page #</b>
CS Version Latest	2936	Y	235E	411
Over-ride SS/NODESPOS	1981	Y	236A	413
Over-ride SS/TNM-N	1982	Y	236B	414
Over-ride SS/TNM-M	1983	Y	236C	415
Over-ride SS/DISMET1	1984	Y	236D	416
Over-ride SEQNO/DXCONF	2000	Y	236E	417
Over-ride SITE/LAT/SEQNO	2010	Y	236F	418
Over-ride Report Source	2050	ACR Use Only	236G	419
Over-ride ILL-Define Site	2060	ACR Use Only	236H	420
Over-ride SITE/EOD/DX DT	2072	N	236I	421
Over-ride SITE/LAT/EOD	2073	N	236J	422
Appendix A: Definitions of Single and Subsequent Primaries for Hematologic			239	425
Appendix B: Site-Specific Surgery Codes			249	435
Appendix C: FORDS Page Revisions			289	475
Index			337	523